Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vitrectomy Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Dropless Pars Plana Vitrectomy Study

NCT05331664
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment
Interventions
Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin, Prednisolone 1%, Atropine 1%
Procedure · Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy

NCT00986362
View directory record Official record
Conditions
Vitrectomy
Interventions
Ocriplasmin, Placebo
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
Up to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 22, 2026, 2:23 PM EDT
Terminated Not applicable Interventional Results available

Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery

NCT01788475
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone
Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 22, 2026, 2:23 PM EDT
Completed Phase 1 Interventional

A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy

NCT01487070
View directory record Official record
Conditions
PDR
Interventions
Macugen (Pegaptanib Sodium)
Drug
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
Up to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Oct 22, 2026, 2:23 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema

NCT00799227
View directory record Official record
Conditions
Diabetic Macular Edema, Vitrectomy
Interventions
Dexamethasone
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 22, 2026, 2:23 PM EDT
Not yet recruiting Phase 4 Interventional

Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.

NCT07864480
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabetes
Interventions
PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab
Device · Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 2:23 PM EDT
Recruiting Phase 4 Interventional

High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy

NCT06662994
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
Drug
Lead sponsor
Retina Consultants of Orange County
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 22, 2026, 2:23 PM EDT
Terminated No phase listed Observational

Necessity of Post-operative Eye Drops

NCT07396831
View directory record Official record
Conditions
Pars Plana Vitrectomy, Scleral Buckling, Surgical Outcomes, Infection Prophylaxis
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 22, 2026, 2:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Beveled-Tip Versus(vs) Standard-Tip Vitrectomy Probe

NCT04076072
View directory record Official record
Conditions
Vitrectomy
Interventions
Utravit High-Speed 10000 cpm Beveled Probe, standard vitrector probe- Alcon (non-beveled) Ultravit 7500 cpm
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 22, 2026, 2:23 PM EDT
Completed Not applicable Interventional

EFFECTIVENESS AND SAFETY ASSESSMENT OF THE VISTA VITRECTOMY PROBE

NCT07140692
View directory record Official record
Conditions
Vitreous Floaters, Vitreous Opacities
Interventions
Vitrectomy
Device
Lead sponsor
The Eye Centers of Racine and Kenosha
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kenosha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Oct 22, 2026, 2:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Intravitreal Injection Site and Perceived Pain

NCT05640895
View directory record Official record
Conditions
Pain
Interventions
Intravitreal injection site
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 100 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 22, 2026, 2:23 PM EDT
Completed Not applicable Interventional Results available

Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy

NCT01257698
View directory record Official record
Conditions
Macular Hole, Retinal Detachment
Interventions
Dorzolamide 2%-timolol 0.5% topical eyedrops
Drug
Lead sponsor
Mid Atlantic Retina
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 22, 2026, 2:23 PM EDT
Withdrawn Not applicable Interventional

Intravitreal Gas for Vitreomacular Adhesion

NCT02001701
View directory record Official record
Conditions
Vitreomacular Adhesion
Interventions
Intravitreal Injection of sulfahexafluoride gas
Procedure
Lead sponsor
Northern California Retina Vitreous Associates
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 22, 2026, 2:23 PM EDT
Terminated Phase 2 Interventional

Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal

NCT00333060
View directory record Official record
Conditions
Epiretinal Membrane, Macular Hole
Interventions
OT-551 ophthalmic solution
Drug
Lead sponsor
Othera Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
16
States / cities
Peoria, Arizona • Beverly Hills, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Oct 22, 2026, 2:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)

NCT00996437
View directory record Official record
Conditions
Vitreous Hemorrhage, Proliferative Diabetic Retinopathy
Interventions
Ranibizumab, Saline
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
67
States / cities
Phoenix, Arizona • Irvine, California • Loma Linda, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 22, 2026, 2:23 PM EDT
Completed No phase listed Observational

International Consortium Investigating Early Vitrectomy in Diabetic Macular Edema Patients

NCT02639507
View directory record Official record
Conditions
Diabetes With Diabetic Retinopathy With Macular Edema
Interventions
Vitrectomy
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 22, 2026, 2:23 PM EDT
Completed Not applicable Interventional Results available

iCare vs Tonopen vs Goldmann Applanation Post-vitrectomy Surgery

NCT01786954
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Icare rebound tonometry, Tonopen applanation, Goldmann applanation
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 22, 2026, 2:23 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Safety and Performance of the Vista Probe for Vitrectomy Surgery

NCT05689333
View directory record Official record
Conditions
Vitrectomy
Interventions
Vista Vitrectomy Probe
Device
Lead sponsor
VISTA Ophthalmics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Bradenton, Florida • Bala-Cynwyd, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 22, 2026, 2:23 PM EDT
Terminated Early Phase 1 Interventional

Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

NCT06056596
View directory record Official record
Conditions
Retinal Detachment, Rhegmatogenous Retinal Detachment
Interventions
Lamivudine 300 MG, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 2:23 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy

NCT01229410
View directory record Official record
Conditions
Vitrectomy
Interventions
400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Oct 22, 2026, 2:23 PM EDT
Completed Not applicable Interventional

Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma

NCT01460810
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
1000CsK Silicon Oil Tamponade
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 22, 2026, 2:23 PM EDT
Recruiting Phase 3 Interventional

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

NCT06790784
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy (PDR)
Interventions
Vitrectomy, Endolaser, Faricimab, Panretinal Photocoagulation (PRP)
Procedure · Device · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
34
States / cities
Huntington Beach, California • Loma Linda, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 2:23 PM EDT
Completed Not applicable Interventional

The Effects of a Music Therapist Designed Listening Program on Intraoperative Vitrectomy

NCT03147235
View directory record Official record
Conditions
Pain, Postoperative, Music Therapy
Interventions
vitrectomy with music listening
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 22, 2026, 2:23 PM EDT